TY  -  
T1  - Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer 
SN  -  /  
UR  - http://hdl.handle.net/10138/333053 
T3  -  
A1  - Eurola, Annika; Ristimäki, Ari; Mustonen, Harri; Nurmi, Anna-Maria; Hagström, Jaana; Haglund, Caj; Seppänen, Hanna 
A2  -  
PB  -  
Y1  - 2021 
LA  - eng 
AB  - Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvant and 143 upfront surgery patients using two antibodies. We developed a six-tier grading scheme for neoadjuvant responses evaluating the remaining tumor cells in surgical specimens. Strong podocalyxin immunopo... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - HUMAN PROTEIN ATLAS; POOR-PROGNOSIS; DUCTAL ADENOCARCINOMA; MAJOR SIALOPROTEIN; EXPRESSION; SURVIVAL; CHEMORADIOTHERAPY; CHEMORADIATION; GEMCITABINE; VALIDATION; 3122 Cancers 
N1  -   
PP  -  
ER  -